ELV

SEC source: 0001156039-25-000032 · wk-form4_1741211844.xml · nonDerivative · entry 2

Penczek Ronald W · CIK 0001659075 · CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,869

F2 · shares: Represents restricted share units. Restrictions lapse as follows: 95 shares on 3/3/2026, 3/3/2027 and 3/3/2028.

SEC source: 0001156039-25-000032 · wk-form4_1741211844.xml · nonDerivative · entry 1

Penczek Ronald W · CIK 0001659075 · CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,584

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-25-000030 · wk-form4_1741211588.xml · derivative · entry 3

LAVU RATNAKAR · CIK 0001737620 · EVP, Chief Digital & Info Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,902

Underlying: Common Stock · 8,902 shares

Expires 2035-03-03

F3 · derivative.exercise_date: The option represents a right to purchase a total of 8,902 shares, and is exercisable in three annual installments, with two installments of 2,967 shares each and one installment of 2,968 shares, beginning on 3/3/2026, which is the one-year anniversary of the option grant date.

SEC source: 0001156039-25-000030 · wk-form4_1741211588.xml · nonDerivative · entry 2

LAVU RATNAKAR · CIK 0001737620 · EVP, Chief Digital & Info Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,783

F2 · shares: Represents restricted share units. Restrictions lapse as follows: 779 shares on 3/3/2026, and 780 shares each on 3/3/2027 and 3/3/2028.

SEC source: 0001156039-25-000030 · wk-form4_1741211588.xml · nonDerivative · entry 1

LAVU RATNAKAR · CIK 0001737620 · EVP, Chief Digital & Info Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,444

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-25-000028 · wk-form4_1741211429.xml · derivative · entry 4

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,549

Underlying: Common Stock · 11,549 shares

Expires 2035-03-03

F4 · derivative.exercise_date: The option represents a right to purchase a total of 11,549 shares, and is exercisable in three annual installments, with one installment of 3,849 shares and two installments of 3,850 shares each, beginning on 3/3/2026, which is the one-year anniversary of the option grant date.

SEC source: 0001156039-25-000028 · wk-form4_1741211429.xml · nonDerivative · entry 3

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,939

F3 · shares: Represents performance based restricted share units. Restrictions lapse on 3/3/2025.

SEC source: 0001156039-25-000028 · wk-form4_1741211429.xml · nonDerivative · entry 2

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,726

F2 · shares: Represents restricted share units. Restrictions lapse as follows: 1,011 shares on 3/3/2026, and 1,012 shares each on 3/3/2027 and 3/3/2028.

SEC source: 0001156039-25-000028 · wk-form4_1741211429.xml · nonDerivative · entry 1

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,691

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-25-000024 · wk-form4_1741211054.xml · derivative · entry 3

Kaye Mark · CIK 0001748691 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,713

Underlying: Common Stock · 13,713 shares

Expires 2035-03-03

F4 · derivative.exercise_date: The option represents a right to purchase a total of 13,713 shares, and is exercisable in three annual installments of 4,571 shares each, beginning on 3/3/2026, which is the one-year anniversary of the option grant date.

SEC source: 0001156039-25-000024 · wk-form4_1741211054.xml · nonDerivative · entry 2

Kaye Mark · CIK 0001748691 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,565

F2 · shares: Represents restricted share units. Restrictions lapse as follows:1,201 shares each on 3/3/2026 and 3/3/2027, and 1,202 shares on 3/3/2028.

F3 · balance_after: Balance includes 17.59 shares acquired on December 20, 2024 through a dividend reinvestment plan.

SEC source: 0001156039-25-000024 · wk-form4_1741211054.xml · nonDerivative · entry 1

Kaye Mark · CIK 0001748691 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,961

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-25-000026 · wk-form4_1741211306.xml · derivative · entry 4

Haytaian Peter D · CIK 0001608538 · EVP & Pres Carelon & CarelonRx

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,549

Underlying: Common Stock · 11,549 shares

Expires 2035-03-03

F4 · derivative.exercise_date: The option represents a right to purchase a total of 11,549 shares, and is exercisable in three annual installments, with one installment of 3,849 shares and two installments of 3,850 shares each, beginning on 3/3/2026, which is the one-year anniversary of the option grant date.

SEC source: 0001156039-25-000026 · wk-form4_1741211306.xml · nonDerivative · entry 3

Haytaian Peter D · CIK 0001608538 · EVP & Pres Carelon & CarelonRx

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,004

F3 · shares: Represents performance based restricted share units. Restrictions lapse on 3/3/2025.

SEC source: 0001156039-25-000026 · wk-form4_1741211306.xml · nonDerivative · entry 2

Haytaian Peter D · CIK 0001608538 · EVP & Pres Carelon & CarelonRx

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,791

F2 · shares: Represents restricted share units. Restrictions lapse as follows: 1,011 shares on 3/3/2026, and 1,012 shares each on 3/3/2027 and 3/3/2028.

SEC source: 0001156039-25-000026 · wk-form4_1741211306.xml · nonDerivative · entry 1

Haytaian Peter D · CIK 0001608538 · EVP & Pres Carelon & CarelonRx

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,756

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-25-000022 · wk-form4_1741210952.xml · derivative · entry 5

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,429

Underlying: Common Stock · 40,429 shares

Expires 2035-03-03

F4 · derivative.exercise_date: The option represents a right to purchase a total of 40,429 shares, and is exercisable in three annual installments, with two installments of 13,476 shares each and one installment of 13,477 shares, beginning on 3/3/2026, which is the one-year anniversary of the option grant date.

SEC source: 0001156039-25-000022 · wk-form4_1741210952.xml · nonDerivative · entry 3

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,520

F3 · shares: Represents performance based restricted share units. Restrictions lapse on 3/3/2025.

SEC source: 0001156039-25-000022 · wk-form4_1741210952.xml · nonDerivative · entry 2

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,933

F2 · shares: Represents restricted share units. Restrictions lapse as follows: 3,540 shares on 3/3/2026, 3/3/2027 and 3/3/2028.

SEC source: 0001156039-25-000022 · wk-form4_1741210952.xml · nonDerivative · entry 1

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,313

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-25-000003 · wk-form4_1736284937.xml · nonDerivative · entry 2

Todt Blair Williams · CIK 0001456430 · EVP, CLO & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,631

F2 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-24-000133 · wk-form4_1730842138.xml · nonDerivative · entry 2

Kendrick Charles Morgan JR · CIK 0001887908 · EVP & President, Commercial

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,287

F2 · shares: Represents performance based restricted share units. Restrictions lapse on 11/1/2024.

SEC source: 0001156039-24-000133 · wk-form4_1730842138.xml · nonDerivative · entry 1

Kendrick Charles Morgan JR · CIK 0001887908 · EVP & President, Commercial

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,577

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-24-000131 · wk-form4_1730842008.xml · nonDerivative · entry 2

Haytaian Peter D · CIK 0001608538 · EVP & Pres Carelon & CarelonRx

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,037

F2 · shares: Represents performance based restricted share units. Restrictions lapse on 11/1/2024.

SEC source: 0001156039-24-000131 · wk-form4_1730842008.xml · nonDerivative · entry 1

Haytaian Peter D · CIK 0001608538 · EVP & Pres Carelon & CarelonRx

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,238

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-24-000124 · wk-form4_1729286498.xml · nonDerivative · entry 1

Kendrick Charles Morgan JR · CIK 0001887908 · EVP & President, Commercial

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,423

F1 · price: This transaction was executed in multiple trades at prices ranging from $432.08 to $432.32. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001156039-24-000115 · wk-form4_1728074148.xml · nonDerivative · entry 1

Kaye Mark · CIK 0001748691 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,213

F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

SEC source: 0001156039-24-000113 · wk-form4_1722979402.xml · nonDerivative · entry 1

PERU RAMIRO G · CIK 0001192045 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,744

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2024.

SEC source: 0001156039-24-000109 · wk-form4_1721768559.xml · nonDerivative · entry 6

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,709

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2024.

F6 · price: This transaction was executed in multiple trades at prices ranging from $504.1 to $504.99. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001156039-24-000109 · wk-form4_1721768559.xml · nonDerivative · entry 5

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,959

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2024.

F5 · price: This transaction was executed in multiple trades at prices ranging from $503.05 to $503.95. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001156039-24-000109 · wk-form4_1721768559.xml · nonDerivative · entry 4

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,959

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $501.96 to $502.65. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001156039-24-000109 · wk-form4_1721768559.xml · nonDerivative · entry 3

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,209

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2024.

F3 · price: This transaction was executed in multiple trades at prices ranging from $500.83 to $501.79. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001156039-24-000109 · wk-form4_1721768559.xml · nonDerivative · entry 2

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,830

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $499.82 to $500.81. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001156039-24-000109 · wk-form4_1721768559.xml · nonDerivative · entry 1

BOUDREAUX GAIL · CIK 0001287920 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,609

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2024.

SEC source: 0001156039-24-000106 · wk-form4_1721680211.xml · nonDerivative · entry 1

Dixon Robert L JR · CIK 0001524849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,721

SEC source: 0001156039-24-000089 · wk-form4_1715977592.xml · nonDerivative · entry 1

Tallett Elizabeth E · CIK 0001192460 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,291

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000088 · wk-form4_1715977548.xml · nonDerivative · entry 1

STRABLE-SOETHOUT DEANNA D · CIK 0001278726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,045

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000087 · wk-form4_1715977502.xml · nonDerivative · entry 1

Schneider Ryan M. · CIK 0001420501 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,999

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000086 · wk-form4_1715977458.xml · nonDerivative · entry 1

PERU RAMIRO G · CIK 0001192045 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,497

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000085 · wk-form4_1715977421.xml · nonDerivative · entry 1

Neri Antonio F · CIK 0001648401 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,324

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000084 · wk-form4_1715977369.xml · nonDerivative · entry 1

Jallal Bahija · CIK 0001730038 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,187

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000081 · wk-form4_1715977201.xml · nonDerivative · entry 1

DeVore Susan D. · CIK 0001587697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,701

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000082 · wk-form4_1715977280.xml · nonDerivative · entry 1

Dixon Robert L JR · CIK 0001524849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,026

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000083 · wk-form4_1715977324.xml · nonDerivative · entry 1

HAY LEWIS III · CIK 0001182705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,906

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001156039-24-000080 · wk-form4_1715977152.xml · nonDerivative · entry 1

CLARK R KERRY · CIK 0001180776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,039

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

SEC source: 0001415889-24-011527 · form4-04252024_090423.xml · derivative · entry 8

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,043 shares

Expires 2028-07-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001415889-24-011527 · form4-04252024_090423.xml · nonDerivative · entry 6

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,304

F3 · price: This transaction was executed in multiple trades at prices ranging from $532.44 to $533.30. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-011527 · form4-04252024_090423.xml · nonDerivative · entry 5

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,738

F2 · price: This transaction was executed in multiple trades at prices ranging from $531.44 to $532.43. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-011527 · form4-04252024_090423.xml · nonDerivative · entry 4

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-011527 · form4-04252024_090423.xml · derivative · entry 7

Norwood Felicia F · CIK 0001743548 · EVP & President,Gov Health Ben

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,043

Underlying: Common Stock · 5,473 shares

Expires 2028-07-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.